47th week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140341889 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia® (denosumab), Xgeva® (denosumab), Aranesp® (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102). | 2014-11-20 |
20140341890 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LUCENTIS® (ranibizumab), BEXSERO® (meningococcal group B vaccine [rDNA, component, adsorbed]), AIN457 (secukinumab) or RELAXIN® (serelaxin). | 2014-11-20 |
20140341891 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LYXUMIA (lixisenatide), LEMTRADA (alemtuzumab), REGN727/SAR236553 (alirocumab), SAR2405550/BSI-201 (iniparib), OTAMIXABAN (otamixaban), SARILUMAB (sarilumab), LANTUS and LYXUMIA (insulin glargine and lixisenatide) or VISAMERIN/MULSEVO (semuloparin sodium). | 2014-11-20 |
20140341892 | ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES - The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets. | 2014-11-20 |
20140341893 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. | 2014-11-20 |
20140341894 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein. | 2014-11-20 |
20140341895 | PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS - The present invention relates to a peptide antigens derived from | 2014-11-20 |
20140341896 | HUMANIZED ANTI-HUMAN NKG2A MONOCLONAL ANTIBODY - The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies. | 2014-11-20 |
20140341897 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample. | 2014-11-20 |
20140341898 | SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES - The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation. | 2014-11-20 |
20140341899 | COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES - Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment. | 2014-11-20 |
20140341900 | METHODS OF TREATING CANCER - Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. | 2014-11-20 |
20140341901 | COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition. | 2014-11-20 |
20140341902 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS - The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 2014-11-20 |
20140341903 | BIOLOGICAL MATERIALS RELATED TO C-MET - The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided. | 2014-11-20 |
20140341904 | SPARC BINDING SCFVS - The invention provides compositions comprising SPARC binding ScFc and its use. | 2014-11-20 |
20140341905 | SPARC BINDING SCFVS - The invention provides compositions comprising SPARC binding ScFc and its use. | 2014-11-20 |
20140341906 | HETERODIMERIC FC REGIONS, BINDING MOLECULES COMPRISING SAME, AND METHODS RELATING THERETO - The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject. | 2014-11-20 |
20140341907 | BISPECIFIC ANTIBODY FRAGMENTS FOR NEUROLOGICAL DISEASE PROTEINS AND METHODS OF USE - The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases. | 2014-11-20 |
20140341908 | METHODS AND COMPOSITIONS TO MODULATE ANTIVIRAL AND IMMUNE ACTIVITY RESPONSES - The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems. | 2014-11-20 |
20140341909 | CONJUGATION OF BIOMOLECULES USING DIELS-ALDER CYCLOADDITION - A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents. | 2014-11-20 |
20140341910 | ANTI-HUMAN CD52 IMMUNOGLOBULINS - The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia. | 2014-11-20 |
20140341911 | Prevention and Treatment of Amyloidogenic Disease - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto. | 2014-11-20 |
20140341912 | MONOCLONAL ANTIBODIES DIRECTED TO CD52 - The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described. | 2014-11-20 |
20140341913 | METHODS AND COMPOSITIONS FOR TREATING ASTHMA USING ANTI-IL-13 ANTIBODIES - The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof. | 2014-11-20 |
20140341914 | ISOLATED MCPIP AND METHODS OF USE - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed. | 2014-11-20 |
20140341915 | B7-H6 THERAPEUTICALLY ACTIVE MONOCLONAL ANTIBODY AGAINST B7-H6 POLYPEPTIDE - The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory. | 2014-11-20 |
20140341916 | THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA - The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma. | 2014-11-20 |
20140341917 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF - The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer. | 2014-11-20 |
20140341918 | Vaccine for Falciparum Malaria - The invention provides compositions and methods for preventing or reducing the severity of malaria. | 2014-11-20 |
20140341919 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. | 2014-11-20 |
20140341920 | VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1). | 2014-11-20 |
20140341921 | HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases. | 2014-11-20 |
20140341922 | Method for Overcoming Tolerance to Targeted Anti-Cancer Agent - Provided are a pharmaceutical composition for suppressing a resistance to a targeted anticancer drug, which at least one selected from the group consisting of an integrin β3 neutralizing antibody, integrin β3 siRNA, Src inhibitor, and Src siRNA as an active ingredient, and an anticancer supplement. The pharmaceutical composition may increase an anticancer therapeutic effect when administered in combination with a conventional targeted anticancer drug. In addition, the pharmaceutical composition is expected to be used in development of an integrin β3-targeted targeted anticancer drug. | 2014-11-20 |
20140341923 | Human Rhinovirus (HRV) Antibodies - The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis. | 2014-11-20 |
20140341924 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-11-20 |
20140341925 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-11-20 |
20140341926 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER - The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m | 2014-11-20 |
20140341927 | ANTIBODIES AND THEIR USE IN THE TREATMENT, PREVENTION AND DIAGNOSIS OF A DISEASE ASSOCIATED WITH SOD1 ABNORMALITIES - The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human. | 2014-11-20 |
20140341928 | Stabilized Formulations Containing Anti-PCSK9 Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2014-11-20 |
20140341929 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 2014-11-20 |
20140341930 | Systems and Methods for Diminishing Cell Growth and Inducing Selective Killing of Target Cells - The invention relates to a biological system for diminishing cell growth or inducing selective killing of target cells, in particular pathogenic bacterial or fungal cells, or cancer cells. The biological system is based on toxin-antitoxin systems, as found in prokaryotic plasmids and their host chromosomes. The biological system comprises a vehicle with a first nucleic acid sequence or amino acid sequence encoding for a prokaryotic toxin of a prokaryotic toxin-antitoxin pair, and a second nucleic acid sequence or amino acid sequence encoding for the corresponding prokaryotic antitoxin of the prokaryotic toxin-antitoxin pair. The system is characterized in that the toxin and/or the antitoxin is operably linked to a protein output modifier (POM) that comprises a nucleic acid sequence or amino acid sequence that modifies the relative rate of transcription, mRNA stability, mRNA translatability or protein stability of the toxin and/or antitoxin. | 2014-11-20 |
20140341931 | SOLUBLE CD27 (SCD27) AND THE USE THEREOF - Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of sCD27 in a serum sample obtained from a subject and comparing that amount of sCD27 with a control value indicative of the basal level of sCD27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of sCD27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor. The disclosed methods can be used to monitoring disease progression in a subject or determine a subject's suitability for immunotherapy. Also disclosed are methods of stimulating a subject's immune system by administering a therapeutically effective amount of sCD27 or a functional fragment. | 2014-11-20 |
20140341932 | Novel pepetides - The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions. | 2014-11-20 |
20140341933 | USE OF PDL1 EXPRESSING CELLS TO CONVERT T CELLS INTO REGULATORY T CELLS - The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases. | 2014-11-20 |
20140341934 | PROCESS FOR EXTRACTING MATERIALS FROM BIOLOGICAL MATERIAL - The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid. | 2014-11-20 |
20140341935 | MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE - A vaccine and method of treatment suitable for treating autoimmune diseases, such as Vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 DNA sequence encoding the peptide. | 2014-11-20 |
20140341936 | Novel Clostridium Difficile DNA Vaccine - The invention relates to compositions and methods for treating | 2014-11-20 |
20140341937 | Methods and Compositions for Modulating Immune Tolerance - The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection. | 2014-11-20 |
20140341938 | NANOPARTICLE-PEPTIDE COMPOSITIONS - The present invention provides nanoparticles and compositions comprising such nanoparticles, as well as methods for intracellular delivery of peptides, and methods of producing nanoparticles and related products. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises a peptide of choice that is covalently linked to the core via a second linker. The second linker comprises a peptide portion and a non-peptide portion, wherein said peptide portion of said second linker comprises the sequence X | 2014-11-20 |
20140341939 | MODIFICATION OF HELPER T CELL-INDUCING POLYPEPTIDE - The present invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using same. | 2014-11-20 |
20140341940 | IMMUNOMODULATOR FOR THE TREATMENT OF CANCEROUS TUMORS IN THE EPITHELIAL TISSUE LINING SURFACES INSIDE OR OUTSIDE BODY ORGANS - The present invention provides a new treatment for noninvasive cancers in the epithelial tissue lining inside and outside surfaces, including the topical use of the immunomodulator, either alone or in association or combination with other drug and non-drug treatments. | 2014-11-20 |
20140341941 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 2014-11-20 |
20140341942 | Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides - This disclosure relates to modified | 2014-11-20 |
20140341943 | EHRLICHIA EWINGII PROTEINS, NUCLEIC ACIDS, AND METHODS OF THEIR USE - The novel omp-1 gene cluster encoding twenty one | 2014-11-20 |
20140341944 | PROTEINS COMPRISING MRSA PBP2A AND FRAGMENTS THEREOF, NUCLEIC ACIDS ENCODING THE SAME, AND COMPOSITIONS AND THEIR USE TO PREVENT AND TREAT MRSA INFECTIONS - Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual. | 2014-11-20 |
20140341945 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine). | 2014-11-20 |
20140341946 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 2014-11-20 |
20140341947 | IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS - The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by | 2014-11-20 |
20140341948 | ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS - The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. | 2014-11-20 |
20140341949 | VACCINE - The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol. | 2014-11-20 |
20140341950 | RECOMBINANT AVIAN PARAMYXOVIRUS VACCINE AND METHOD FOR MAKING AND USING THEREOF - The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV. | 2014-11-20 |
20140341951 | METHOD OF TREATMENT EMPLOYING THERAPEUTIC T CELL PRODUCT FROM MOBILISED DONORS - The present disclosure provides a method of treating a human patient in need thereof with immune reconstitution therapy by administering a therapeutically effective amount of therapeutic T cell population selected and/or expanded from a mobilised blood sample or a mobilised apheresis sample, wherein selection is on the basis of a steady state marker and/or an activation marker optionally followed by expansion, or expansion is in the presence of antigen, such as a viral antigen. It also extends to methods of generating said therapeutic T cell populations and the product obtainable therefrom. | 2014-11-20 |
20140341952 | METHOD OF TREATMENT OF DISEASES USING HOODIA EXTRACTS - A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus | 2014-11-20 |
20140341953 | BUBBLE ENCAPSULATION VIA SILICILIC ACID COMPLEXATION - Disclosed are methods of preparing stable gas-in-water dispersions by silicic acid complexation of micron-sized gas bubbles, and stable dispersions prepared by silicic acid complexation. Compositions and products comprising the dispersions are also disclosed. Dispersions may be stable over an extended period of time at room temperature. | 2014-11-20 |
20140341954 | STABLE EMULSIONS VIA PARTICLE ABSORPTION BY ELECTROSTATIC INTERACTION - Disclosed are methods of preparing stable O/W emulsions by particle adsorption via electrostatic interaction, and stable emulsions prepared by particle adsorption via electrostatic interaction. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 2014-11-20 |
20140341955 | STABLE BUBBLES VIA PARTICLE ABSORPTION BY ELECTROSTATIC INTERACTION - Disclosed are methods of preparing stable gas-in-solution emulsions by particle adsorption via electrostatic interaction, and stable emulsions prepared by particle adsorption via electrostatic interaction. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 2014-11-20 |
20140341956 | ANTI-UV COMPOSITION FOR PROTECTING SCALP - Disclosed herein is a anti-UV composition for protecting the scalp. The anti-UV composition for protecting the scalp of the present invention includes a fermented broth of Outtuynia | 2014-11-20 |
20140341957 | Surfactant Responsive Dispersion Polymerized Micro-Gels - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The crosslinked, nonionic amphiphilic polymer is prepared by dispersion polymerization in the presence of a stabilizing polymer. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization. | 2014-11-20 |
20140341958 | SILICA MICROCAPSULES, PROCESS OF MAKING THE SAME AND USES THEREOF - The present document describes a microcapsule having silica shells, processes for making the same, processes for functionalizing said microcapsules and processes for encapsulating active agent in said microcapsules. | 2014-11-20 |
20140341959 | COSMETIC COMPOSITION CARRIER CONTAINING URETHANE FOAM LAYER STRUCTURE - Disclosed are a cosmetic composition carrier containing a urethane foam layer structure, and cosmetics including the cosmetic composition carrier that contains a cosmetic composition. | 2014-11-20 |
20140341960 | GELLING AGENT - Provided is a gelling agent containing N-acyl acidic amino acid dialkylamide having a DL form ratio (D form/L form (weight/weight)) of 5/95-20/80 or 80/20-95/5, and using the gelling agent, a gel composition, particularly a rod-like gel composition, superior in transparency and strength, and superior in compatibility and spreadability when applied to the skin, hair and the like is provided. | 2014-11-20 |
20140341961 | MATERIAL FOR FORMING A MULTI-LEVEL ANTIMICROBIAL SURFACE COATING AND ITS PREPARATION - The present invention provides a method for preparing a material in the form of liquid for forming an antimicrobial surface coating with multi-level antimicrobial properties, comprising: encapsulating one or more volatile or gaseous biocides in two or more amphiphilic block copolymers to obtain a w/o/w double emulsion, and mixing the w/o/w double emulsion with one or more nonvolatile biocides, each of which is selected from the group consisting of a metal containing biocide, triclosan, a carboxylic acid, a sugar acid and a combination thereof. | 2014-11-20 |
20140341962 | ENCAPSULATED ACTIVES - A composition is provided with increased release comprising an encapsulated active and one or more metal additive. Also provided is a coating composition comprising an encapsulated active, and one or more metal additive, and one or more binder polymer, one or more binder precursor, or a mixture thereof, and one or more pigment. Also provided is a method of making such compositions. Also provided is a method of providing a surface that resists marine fouling wherein said method comprises applying a layer of such compositions to a substrate and drying said layer or allowing said layer to dry. | 2014-11-20 |
20140341963 | Device for the Treatment of Bone Conditions - A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions. | 2014-11-20 |
20140341964 | COHESIVE OSTEOGENIC PUTTY AND MATERIALS THEREFOR - Described is an implantable medical material comprising a malleable, cohesive, shape-retaining putty including mineral particles, insoluble collagen fibers and soluble collagen. The medical material can be used in conjunction with biologically active factors such as osteogenic proteins to treat bone or other tissue defects in patients. | 2014-11-20 |
20140341965 | Compositions and Methods Comprising Biodegradable Scaffolds and Retinal Pigment Epithelial Cells - The invention relates to compositions comprising a monolayer of functional retinal pigment epithelial (RPE) cells attached to a transplantable, biodegradable scaffold. The invention also relates to methods of using these compositions. | 2014-11-20 |
20140341966 | STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent. | 2014-11-20 |
20140341967 | Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 2014-11-20 |
20140341968 | Intraocular Drug Delivery Systems - Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer. | 2014-11-20 |
20140341969 | WOUND DRESSING - The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly. | 2014-11-20 |
20140341970 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 2014-11-20 |
20140341971 | COMPOSITION FOR TARGETING DENDRITIC CELLS - The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma. | 2014-11-20 |
20140341972 | METHOD TO INDUCE NEOVASCULAR FORMATION AND TISSUE REGENERATION - The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium. | 2014-11-20 |
20140341973 | MICRON TAIWANOFUNGUS CAMPHORATUS LIPOSOME STRUCTURE - A micron Taiwanofungus camphoratus liposome structure which includes a first and a second liposome shell is provided. The external radius of the first liposome shell is smaller than the internal radius of the second liposome shell, and the second liposome shell encloses the first liposome shell. A first space is defined inside of the first liposome shell, and a second space is defined between the inside surface of the second liposome shell and the outside surface of the first liposome shell. A plurality of cup-shaped structures is formed on the outside surface of the second liposome shell. Each cup-shaped structure is consisted of algae sugar and beta-cyclodextrin. The first space and the second space are for containing a first and a second active substance respectively. The Taiwanofungus camphoratus liposome structure contains active substances with different effects, such that the storage and transportation of multi-active substances is improved. | 2014-11-20 |
20140341974 | Liposomal Vaccine Adjuvants and Methods of Making and Using Same - A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen. | 2014-11-20 |
20140341975 | PATHOGEN AND SUBSTANCE TRAPS - A composition-of-matter is provided as well as pharmaceutical compositions and methods of using same. The composition of matter includes least one active moiety surrounded by a scaffold configured for enabling selective influx of an agent capable of interacting with the at least one active moiety. | 2014-11-20 |
20140341976 | COMPOSITIONS AND METHODS FOR INHIBITING "STIMULATOR OF INTERFERON GENE" -DEPENDENT SIGNALLING - The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon. | 2014-11-20 |
20140341977 | TREATMENT OF AMD USING AAV SFLT-1 - The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | 2014-11-20 |
20140341978 | CANCER IMMUNOTHERAPY - We formulated multiple TLR agonists into GVAX (lethally irradiated tumor cell vaccines engineered to secrete GM-CSF). Specifically, GLA and R848, TLR4 and TLR7/8 agonists found to be safe in patients, were formulated with GVAX (TEGVAX—for TLR agonists enhanced GVAX), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable B16. These anti-tumor responses were correlated with increased CD4 and CD8 T-cells that can secrete IFNγ circulating in the tumor microenvironment as well as significantly higher level of p15E specific CTL mediated cell killing in mice treated with TEGVAX in comparison to controls. When combined with anti-PD-1 antibody, TEGVAX was able to induce regression of established B16 tumors. | 2014-11-20 |
20140341979 | NANODRUG TARGETING PROTEIN GERANYLGERANYLATION - The present invention relates, for example, to a liposome, which can be a basic liposome, a transferrin-conjugated liposome, or a pH-sensitive liposome, which encapsulates a compound that specifically inhibits the activity of a protein prenyltransferase, such as a RabGGTase and/or a GGTase I. The liposomes can be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits. | 2014-11-20 |
20140341980 | Method to Enhance an Immune Response of Nucleic Acid Vaccination - A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein. | 2014-11-20 |
20140341981 | EMULSION STABILIZATION VIA SILICILIC ACID COMPLEXATION - Disclosed are methods of preparing stable O/W emulsions by silicic acid complexation of micron-sized oil droplets, and stable emulsions prepared by silicic acid complexation. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 2014-11-20 |
20140341982 | Vaccination With Immuno-Isolated Cells Producing An Immunomodulator - The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used for vaccination where they provide the immunomodulator in an active form, in a continuous, non-immunogenic manner in the immediate vicinity of the vaccine antigen(s). The invention also relates to a vaccine composition comprising immuno-protected encapsulated cells producing an immunomodulator and an antigenic component. The invention also relates to a kit comprising a cell as described and an antigenic component. The strategy of the invention is perfectly suited for both cancer immunotherapy and vaccination against infectious agents. | 2014-11-20 |
20140341983 | SMART.TM. SOLID ORAL DOSAGE FORMS - Solid Oral Dosage Forms (SODFs) comprising Self Monitoring and Reporting Therapeutics (SMART™) adherence technology are provided which require no or minimal modification of clinical trial materials (CTMs) or marketed drug while providing tamper resistant (literally foolproof) measurement of adherence that is highly accurate and without altering the chemical, manufacturing, and controls (CMC) of the CTM or marketed drug. | 2014-11-20 |
20140341984 | TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS - Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising a compressed core comprising: (i) an active agent susceptible to abuse and (ii) a gelling agent; wherein the plurality of particles contains a therapeutically or prophylactically effective amount of the active agent; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration. | 2014-11-20 |
20140341985 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 2014-11-20 |
20140341986 | Biguanide Compositions and Methods of Treating Metabolic Disorders - Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 2014-11-20 |
20140341987 | COLOUR CHANGING COMPOSITION IN O/W EMULSION FORM - A changing colour composition for caring for and/or making up keratin materials on the form of an O/W emulsion comprising, in a physiologically acceptable medium, at least a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least 5% by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols C2-C8 monoalcohols and mixtures thereof, c) non entrapped Ti0 | 2014-11-20 |
20140341988 | ORALLY DISPERSIBLE DRUG FORMULATIONS - Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered. | 2014-11-20 |